A Randomized Phase III Evaluation of Docetaxel (NSC 628503) and Gemcitabine (NSC 613327) Plus G-CSF With Bevacizumab (NSC 704865, IND 7921) Versus Docetaxel (NSC 628503) and Gemcitabine (NSC 613327) Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus

Trial Profile

A Randomized Phase III Evaluation of Docetaxel (NSC 628503) and Gemcitabine (NSC 613327) Plus G-CSF With Bevacizumab (NSC 704865, IND 7921) Versus Docetaxel (NSC 628503) and Gemcitabine (NSC 613327) Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus

Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Docetaxel; Filgrastim; Gemcitabine; Pegfilgrastim
  • Indications Leiomyosarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Apr 2013 New source identified and integrated (M.D. Anderson Cancer Center; GOG0250).
    • 14 Jan 2013 New source identified and integrated (Mayo Clinic, 10-000042).
    • 27 Dec 2012 Planned end date changed from 1 Jan 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top